The Experts below are selected from a list of 147 Experts worldwide ranked by ideXlab platform

Isidro B. Salusky - One of the best experts on this subject based on the ideXlab platform.

  • vitamin d sterols increase fgf23 expression by stimulating osteoblast and osteocyte maturation in ckd bone
    Bone, 2019
    Co-Authors: Renata C Pereira, Isidro B. Salusky, Richard E Bowen, Earl Freymiller, Katherine Wesselingperry
    Abstract:

    Abstract Impaired osteoblast and osteocyte maturation contribute to mineralization defects and excess FGF23 expression in CKD bone. Vitamin D sterols decrease osteoid accumulation and increase FGF23 expression; these agents also increase osteoblast maturation in vitro but a link between changes in bone cell maturation, bone mineralization, and FGF23 expression in response to vitamin D sterols has not been established. We evaluated unmineralized osteoid accumulation, osteocyte maturity markers (FGF23: early osteocytes; sclerostin: late osteocytes), and osteocyte apoptosis in iliac crest of 11 pediatric dialysis patients before and after 8 months of Doxercalciferol therapy. We then evaluated the effect of 1,25(OH)2vitamin D on in vitro maturation and mineralization of primary osteoblasts from dialysis patients. Unmineralized osteoid accumulation decreased while numbers of early (FGF23-expressing) increased in response to Doxercalciferol. Osteocyte apoptosis was low but increased with Doxercalciferol. Bone FGF23 expression correlated with numbers of early, FGF23-expressing, osteocytes (r = 0.83, p

  • RESEARCH ARTICLE Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients
    2016
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky
    Abstract:

    Background Osteocytic protein expression is dysregulated in CKD and is affected by changes in mineral metabolism; however the effects of active vitamin D sterol therapy on osteocyte protein ex-pression in advanced CKD is unknown. Methods Eleven pediatric patients with end stage kidney disease underwent bone biopsy, were treat-ed for 8 months with Doxercalciferol, and then underwent a second bone biopsy. Bone ex-pression of fibroblast growth factor 23 (FGF23), dentin matrix protein 1 (DMP1), and sclerostin were determined by immunohistochemistry and quantified by Ariol Scanning. Western blot analysis and qRT-PCR was performed on bone abstracts of a subset of study subjects to determine the nature (i.e. size) of FGF23 and DMP1 in bone before and after therapy. Results As assessed by immunohistochemistry, bone FGF23, DMP1 and sclerostin protein all in

  • Correlation between changes in bone DMP1 expression and prescribed Doxercalciferol dose.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    Correlation between changes in bone DMP1 expression and prescribed Doxercalciferol dose.

  • Changes in bone DMP1 expression with Doxercalciferol therapy.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    a) The quantification of DMP1 mRNA (qRT-PCR) transcript and DMP1 protein as detected by immunohistochemistry (IHC). For qRT-PCR, gene expression in dialysis patients before and after Doxercalciferol therapy was expressed relative to normal control and was calculated as 2^(ΔCt DMP1)/2^ (ΔCt GAPDH). Individual data points are shown; the bar indicates the median value. The number sign indicates a significant (p

  • Changes in bone FGF23 expression with Doxercalciferol therapy.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    a) The quantification of FGF23 mRNA (qRT-PCR) transcript and FGF23 protein as detected by immunohistochemistry (IHC). For qRT-PCR, gene expression in dialysis patients before and after Doxercalciferol therapy was expressed relative to normal control and was calculated as 2^(ΔCt FGF23)/2^ (ΔCt GAPDH). Individual data points are shown; the bar indicates the median value. The number sign indicates a significant (p

Harald Juppner - One of the best experts on this subject based on the ideXlab platform.

Barbara Gales - One of the best experts on this subject based on the ideXlab platform.

Renata C Pereira - One of the best experts on this subject based on the ideXlab platform.

  • vitamin d sterols increase fgf23 expression by stimulating osteoblast and osteocyte maturation in ckd bone
    Bone, 2019
    Co-Authors: Renata C Pereira, Isidro B. Salusky, Richard E Bowen, Earl Freymiller, Katherine Wesselingperry
    Abstract:

    Abstract Impaired osteoblast and osteocyte maturation contribute to mineralization defects and excess FGF23 expression in CKD bone. Vitamin D sterols decrease osteoid accumulation and increase FGF23 expression; these agents also increase osteoblast maturation in vitro but a link between changes in bone cell maturation, bone mineralization, and FGF23 expression in response to vitamin D sterols has not been established. We evaluated unmineralized osteoid accumulation, osteocyte maturity markers (FGF23: early osteocytes; sclerostin: late osteocytes), and osteocyte apoptosis in iliac crest of 11 pediatric dialysis patients before and after 8 months of Doxercalciferol therapy. We then evaluated the effect of 1,25(OH)2vitamin D on in vitro maturation and mineralization of primary osteoblasts from dialysis patients. Unmineralized osteoid accumulation decreased while numbers of early (FGF23-expressing) increased in response to Doxercalciferol. Osteocyte apoptosis was low but increased with Doxercalciferol. Bone FGF23 expression correlated with numbers of early, FGF23-expressing, osteocytes (r = 0.83, p

  • RESEARCH ARTICLE Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients
    2016
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky
    Abstract:

    Background Osteocytic protein expression is dysregulated in CKD and is affected by changes in mineral metabolism; however the effects of active vitamin D sterol therapy on osteocyte protein ex-pression in advanced CKD is unknown. Methods Eleven pediatric patients with end stage kidney disease underwent bone biopsy, were treat-ed for 8 months with Doxercalciferol, and then underwent a second bone biopsy. Bone ex-pression of fibroblast growth factor 23 (FGF23), dentin matrix protein 1 (DMP1), and sclerostin were determined by immunohistochemistry and quantified by Ariol Scanning. Western blot analysis and qRT-PCR was performed on bone abstracts of a subset of study subjects to determine the nature (i.e. size) of FGF23 and DMP1 in bone before and after therapy. Results As assessed by immunohistochemistry, bone FGF23, DMP1 and sclerostin protein all in

  • Correlation between changes in bone DMP1 expression and prescribed Doxercalciferol dose.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    Correlation between changes in bone DMP1 expression and prescribed Doxercalciferol dose.

  • Changes in bone DMP1 expression with Doxercalciferol therapy.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    a) The quantification of DMP1 mRNA (qRT-PCR) transcript and DMP1 protein as detected by immunohistochemistry (IHC). For qRT-PCR, gene expression in dialysis patients before and after Doxercalciferol therapy was expressed relative to normal control and was calculated as 2^(ΔCt DMP1)/2^ (ΔCt GAPDH). Individual data points are shown; the bar indicates the median value. The number sign indicates a significant (p

  • Changes in bone FGF23 expression with Doxercalciferol therapy.
    2015
    Co-Authors: Renata C Pereira, Barbara Gales, Isidro B. Salusky, Harald Juppner, Katherine Wesseling-perry
    Abstract:

    a) The quantification of FGF23 mRNA (qRT-PCR) transcript and FGF23 protein as detected by immunohistochemistry (IHC). For qRT-PCR, gene expression in dialysis patients before and after Doxercalciferol therapy was expressed relative to normal control and was calculated as 2^(ΔCt FGF23)/2^ (ΔCt GAPDH). Individual data points are shown; the bar indicates the median value. The number sign indicates a significant (p

Katherine Wesseling-perry - One of the best experts on this subject based on the ideXlab platform.